Wall Street is positive on Corbus Pharmaceuticals Holdings Inc (CRBP). On average, analysts give Corbus Pharmaceuticals Holdings Inc a Buy rating. The average price target is $1.98, which means analysts expect the stock to climb by 607.14% over the next twelve months. That average ranking earns Corbus Pharmaceuticals Holdings Inc an Analyst Rating of 21, which is better than 21% of stocks based on data compiled by InvestorsObserver.
Wall Street analysts are rating CRBP a Buy today. Find out what this means to you and get the rest of the rankings on CRBP!